Lorukafusp alfa

Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity[1].

Product Specifications

CAS Number

[2131168-99-3]

Product Name Alternative

APN-301; hu14.18-IL2; EMD 273063

UNSPSC

12352203

Target

Others

Type

Inhibitory Antibodies

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lorukafusp-alfa.html

Purity

97.8

Solubility

10 mM in DMSO

Smiles

[Lorukafuspalfa]

Molecular Weight

(175.6 kDa)

References & Citations

[1]Suzanne Shusterman, et al. Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study. Clin Cancer Res. 2019 Oct 15;25 (20) :6044-6051.